252 related articles for article (PubMed ID: 35570146)
1. [Comparative Study of PD-L1 Expression in Different Sites of
Non-small Cell Lung Cancer].
Huang X; Wu J; Zhou L; Song Z; Xu W; Jia L; Diao X; Wu Q; Lin D
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):303-310. PubMed ID: 35570146
[TBL] [Abstract][Full Text] [Related]
2. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
Wang H; Agulnik J; Kasymjanova G; Fiset PO; Camilleri-Broet S; Redpath M; Cohen V; Small D; Pepe C; Sakr L; Spatz A
Lung Cancer; 2019 Jun; 132():36-38. PubMed ID: 31097091
[TBL] [Abstract][Full Text] [Related]
3. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
5. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
6. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
7. Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancer.
Avilés-Salas A; Flores-Estrada D; Lara-Mejía L; Catalán R; Cruz-Rico G; Orozco-Morales M; Heredia D; Bolaño-Guerra L; Soberanis-Piña PD; Varela-Santoyo E; Cardona AF; Arrieta O
Thorac Cancer; 2022 Dec; 13(23):3362-3373. PubMed ID: 36317227
[TBL] [Abstract][Full Text] [Related]
8. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
Liam CK; Yew CY; Pang YK; Wong CK; Poh ME; Tan JL; Soo CI; Loh TC; Chin KK; Munusamy V; Liam YS; Ibrahim NH
BMC Cancer; 2023 Jul; 23(1):659. PubMed ID: 37452277
[TBL] [Abstract][Full Text] [Related]
9. Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer.
Fu F; Deng C; Sun W; Zheng Q; Jin Y; Li Y; Zhang Y; Chen H
Respir Res; 2022 Nov; 23(1):302. PubMed ID: 36335353
[TBL] [Abstract][Full Text] [Related]
10. Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study.
Russell PA; Farrall AL; Prabhakaran S; Asadi K; Barrett W; Cooper C; Cooper W; Cotton S; Duhig E; Egan M; Fox S; Godbolt D; Gupta S; Hassan A; Leslie C; Leong T; Moffat D; Qiu MR; Sivasubramaniam V; Skerman J; Snell C; Walsh M; Whale K; Klebe S
Pathology; 2023 Dec; 55(7):922-928. PubMed ID: 37833206
[TBL] [Abstract][Full Text] [Related]
11. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
Dietel M; Savelov N; Salanova R; Micke P; Bigras G; Hida T; Antunez J; Guldhammer Skov B; Hutarew G; Sua LF; Akita H; Chan OSH; Piperdi B; Burke T; Khambata-Ford S; Deitz AC
Lung Cancer; 2019 Aug; 134():174-179. PubMed ID: 31319978
[TBL] [Abstract][Full Text] [Related]
12. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
[TBL] [Abstract][Full Text] [Related]
13. Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.
Saito Y; Horiuchi S; Morooka H; Ibi T; Takahashi N; Ikeya T; Shimizu Y; Hoshi E
J Thorac Dis; 2019 Dec; 11(12):4982-4991. PubMed ID: 32030214
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
Li C; Huang C; Mok TS; Zhuang W; Xu H; Miao Q; Fan X; Zhu W; Huang Y; Lin X; Jiang K; Hu D; Chen X; Huang P; Lin G
J Thorac Oncol; 2017 Oct; 12(10):1536-1543. PubMed ID: 28751245
[TBL] [Abstract][Full Text] [Related]
15. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
Wang G; Ionescu DN; Lee CH; Hiruki T; Myers R; Shaipanich T; Lam S; Melosky B; Zhou C
Lung Cancer; 2019 Oct; 136():1-5. PubMed ID: 31421256
[TBL] [Abstract][Full Text] [Related]
17. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples.
Ilié M; Hofman V; Bontoux C; Goffinet S; Benzaquen J; Heeke S; Boutros J; Lassalle S; Long-Mira E; Zahaf K; Lalvée S; Lespinet-Fabre V; Bordone O; Tanga V; Gómez-Caro A; Cohen C; Berthet JP; Marquette CH; Hofman P
Lung Cancer; 2023 Jul; 181():107230. PubMed ID: 37150140
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.
Aazzane O; Bakhtaoui FZ; Stitou S; Fellah H; Karkouri M
Tunis Med; 2024 Apr; 102(4):223-228. PubMed ID: 38746962
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.
Hwang DM; Albaqer T; Santiago RC; Weiss J; Tanguay J; Cabanero M; Leung Y; Pal P; Khan Z; Lau SCM; Sacher A; Torlakovic E; Cheung C; Tsao MS
J Thorac Oncol; 2021 Sep; 16(9):1490-1500. PubMed ID: 33915250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
